Peptide Modulators for BKCa Channel Trafficking Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological strategies for manipulating BKCa channels are non-specific, affecting other types of channels and causing central effects due to lipophilicity, making them poorly tolerated for conditions like erectile dysfunction.
Innovation Solution
Designing and synthesizing peptide modulators with specific amino acid sequences, such as VEDEC, attached to the C-terminal end of Slo1 protein isoforms, to regulate trafficking and stability of BKCa channels, enhancing their surface expression and functional activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules and natural-products/toxins are used to manipulate BKCa channels, then channel function can be altered, but the approach is non-specific and affects other types of channels
Solution Approach 1:
The patent applies local quality by designing peptides that specifically target the COOH-terminal domain of BKCa channels, which is a unique structural feature. The peptides interact with a specific binding site in this domain, allowing selective modulation of BKCa channels without affecting other channel types. This localized interaction mechanism provides the specificity needed to avoid off-target effects while maintaining therapeutic efficacy.
2Reliability
If lipophilic small molecules are used to manipulate BKCa channels, then channel function can be altered, but central effects occur due to blood-brain barrier penetration
Solution Approach 1:
The patent fundamentally changes the pharmacological parameter of molecule properties by transitioning from lipophilic small molecules to hydrophilic peptides. This parameter change eliminates blood-brain barrier penetration, thereby preventing central effects while maintaining the ability to modulate BKCa channels in peripheral tissues. The peptide's hydrophilic nature ensures it remains excluded from the central nervous system, solving the toxicity problem associated with lipophilic compounds.
3Adaptability or versatility
If existing pharmacological agents are used to increase BKCa channel function, then conditions like erectile dysfunction can be treated, but tolerance is poor due to non-specific actions and central effects
Solution Approach 1:
The patent applies segmentation by dividing the pharmacological approach into two distinct strategies: (1) peptides that increase surface expression of BKCa channels by regulating trafficking, and (2) peptides that modulate channel gating properties. This segmentation allows for more precise and tolerable therapeutic effects, as each peptide class targets a specific mechanism without the non-specific actions of conventional small molecules, thereby improving therapeutic tolerance while maintaining adaptability to various conditions.
Data Source
AI summary
Provided herein are methods of improving electrolyte balance across a cell membrane and treating pathophysiological conditions associated with electrolyte imbalance. Improvement or treatment is effected by ontacting the cell or administering a peptide modulator that increases the surface expression of Ca2+-activated potassium channels. The peptide modulator may comprise a C-terminal sequence such as in SEQ ID NOS: 9 or 10 or a conservative mutant thereof such as in SEQ ID NOS: 12-20 or modifications thereof.